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Abstract
 
Neointimal lesions are characterized by accumulation of cells within the arterial wall and are a
prelude to atherosclerotic disease. Here we report that a brief exposure to either alkyl ether analogs
of the growth factor–like phospholipid lysophosphatidic acid (LPA), products generated during
the oxidative modification of low density lipoprotein, or to unsaturated acyl forms of LPA induce
progressive formation of neointima in vivo in a rat carotid artery model. This effect is completely
inhibited by the peroxisome proliferator-activated receptor (PPAR)
 
 
 
 antagonist GW9662 and
mimicked by PPAR
 
 
 
 agonists Rosiglitazone and 1-
 
O
 
-hexadecyl-2-azeleoyl-phosphatidylcholine.
In contrast, stearoyl-oxovaleryl phosphatidylcholine, a PPAR
 
 
 
 agonist and polypeptide epidermal
growth factor, platelet-derived growth factor, and vascular endothelial growth factor failed to
elicit neointima. The structure-activity relationship for neointima induction by LPA analogs in
vivo is identical to that of PPAR
 
 
 
 activation in vitro and disparate from that of LPA G protein–
coupled receptor activation. Neointima-inducing LPA analogs up-regulated the CD36 scavenger
receptor in vitro and in vivo and elicited dedifferentiation of cultured vascular smooth muscle
cells that was prevented by GW9662. These results suggest that selected LPA analogs are important
novel endogenous PPAR
 
 
 
 ligands capable of mediating vascular remodeling and that activation of
the nuclear transcription factor PPAR
 
 
 
 is both necessary and sufficient for neointima formation by
components of oxidized low density lipoprotein.
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Introduction
 
Atherosclerotic disease is responsible for more than half of
all mortality in developed countries (1–3). Neointima for-
mation is an early step in the development of atherosclerotic
plaques (2, 3). Atherogenic lesions progress through a pro-
longed process of lipid accumulation, calcification, and
inflammation; subsequent rupture of the atherosclerotic
plaque can trigger heart attack and stroke (4, 5). Native low
density lipoprotein (nLDL) is a transporter of phospholipids
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Abbreviations used in this paper:
 
 1AGP, 1-octadecenyl-glycerophosphate;
3AGP, 3-
 
O
 
-octadecenyl-glycerophosphate; Acox, acyl-CoA oxidase;
 
alkyl-GP, alkyl ether glycerophosphate; AZ-PC, 1-
 
O
 
-hexadecyl-2-azeleoyl-
phosphatidylcholine; CCA, common carotid artery; cPA, 2,3-cyclic
phosphatidic acid; DGPP, dioctylglycerol pyrophosphate; EGF, epidermal
growth factor; GPCR, G protein–coupled receptor; hCAD, heavy
caldesmon; IGF, insulin-like growth factor;
 
 
 
LDL, low density lipopro-
tein; LPA, lysophosphatidic acid; moxLDL, minimally oxidized LDL;
nLDL, native LDL; PAF, platelet-activating factor; PDGF, platelet-derived
growth factor; PPAR, peroxisome proliferator-activated receptor; PPRE,
PPAR response element; PTX, pertussis toxin; Rluc, renilla luciferase;
Rosi, Rosiglitazone; S1P, sphingosine 1-phosphate; SOV-PC, stearoyl-
oxovaleryl phosphatidylcholine; TZD, thiazolidinedione; VEGF, vascular
endothelial growth factor; VSMC, vascular smooth muscle cell;
 
 
 
XY-4, 1,1-
difluorodeoxy-(
 
2R
 
)-palmitoyl-
 
sn
 
-glycero-3-phosphate; XY-8, 1-palmitoyl-
(
 
2R
 
)-fluorodeoxy-
 
sn
 
-glycero-3-phosphate. 
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and cholesterol in blood. Oxidative modification of nLDL
by stresses such as cigarette smoke exposure (6) results in
the generation of novel lipid mediators. This process ren-
ders the resulting minimally oxidized LDL (moxLDL)
highly atherogenic (6, 7). We have reported previously that
oxidative modification of LDL leads to the generation of
new, active components with biological and pharmacolog-
ical properties similar to lysophosphatidic acid (LPA) (8).
LPA elicits pleiotropic growth factor–like effects on most
cell types through the activation of four specific G protein–
coupled receptors (GPCRs) (9, 10). Recent evidence sup-
ports a role for LPA as a direct agonist of nuclear tran-
scription factor peroxisome proliferator-activated receptor
(PPAR)
 
 
 
 (11).
LPA is produced in serum after the activation of multiple
biochemical pathways linked to platelet activation and
reaches concentrations at the 10-micromolar range (9, 10).
LPA accumulates in the lipid-rich core of human carotid
atherosclerotic plaques (12). Upon plaque rupture, LPA ac-
tivates platelets and can lead to thrombus formation that is
fully inhibited by antagonists of LPA GPCR (12). Several
bioactive mediators, including LPA, 1-
 
O
 
-hexadecyl-2-aze-
leoyl-phosphatidylcholine (AZ-PC), and stearoyl-oxovaleryl
phosphatidylcholine (SOV-PC), are generated as a result of
oxidative modification of LDL (6, 7, 13). Together, these
 
mediators affect endothelial and vascular smooth muscle
cells (VSMCs) and circulating blood cells including platelets
and macrophages (14–16). Recently, unsaturated acyl spe-
cies of LPA have been reported to elicit neointima forma-
tion in a noninjury model of the rat carotid artery (17). This
study was based on the previous observation that unsatur-
ated acyl species of LPA caused phenotypic dedifferentiation
of cultured VSMCs from the rat aorta (18).
These studies led us to investigate the effects of moxLDL
on the rat carotid artery, identify the active LPA-like lipid
in moxLDL, and characterize the LPA receptor–mediating
neointima formation and VSMC dedifferentiation. Here
we report that a brief exposure to alkyl ether analogs of
LPA, products we found generated during the oxidative
modification of LDL, or to unsaturated acyl forms of LPA,
the predominant species produced as a result of platelet ac-
tivation, induce progressive formation of neointima in vivo
in a noninjury rat carotid artery model. These effects are
completely inhibited by pretreatment with the PPAR
 
 
 
 an-
tagonist GW9662. The structure-activity relationship for
neointima induction by LPA analogs in vivo is identical to
that of PPAR
 
 
 
 activation in vitro and distinct from that of
G protein–coupled LPA receptor activation. Neointima
were elicited by the PPAR
 
 
 
-specific agonists Rosiglita-
zone (Rosi) and AZ-PC; however, neither a PPAR
 
 
 
-
Figure 1. Structural formulas of lipid me-
diators used in the study. 
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selective ligand SOV-PC, nor vascular endothelial growth
factor (VEGF), epidermal growth factor (EGF), and plate-
let-derived growth factor (PDGF) had such an effect. LPA
activated the PPAR-regulated CD36 scavenger receptor
expression in the neointimal tissue and in CV-1 cells trans-
fected with a reporter gene containing the CD36 pro-
moter. Activation of the CD36 reporter was activated by
alkyl ether and unsaturated acyl species of LPA and re-
quired the PPAR response element (PPRE). In cultured
VSMCs, Rosi and LPA 20:4 but not LPA 20:0 elicited
morphological dedifferentiation and down-regulated the
expression of heavy caldesmon (hCAD) mRNA, a marker
of the differentiated phenotype. The morphological dedif-
ferentiation and decrease in hCAD mRNA expression in-
duced by these compounds was reversed by GW9662
treatment. These results suggest that activation of the nu-
clear transcription factor PPAR
 
 
 
 in this model is both nec-
essary and sufficient for neointimal lesion formation.
 
Materials and Methods
 
LPA and sphingosine-1–phosphate (S1P) were from Avanti
Polar Lipids. GW9662 was from Tocris Cookson Inc. Rosi
was from ARC Inc. Stereoisomers of alkyl-glycerophosphate
(alkyl-GP), LPA 18:2, 18:3, 20:0, 20:4, fluorinated LPA
analogs (19, 20), including 1,1-difluorodeoxy-(
 
2R
 
)-palmitoyl-
 
sn
 
-glycero-3-phosphate (XY-4), its regioisomer 1-palmi-
toyl-(
 
2R
 
)-fluorodeoxy-
 
sn
 
-glycero-3-phosphate (XY-8; Fig.
1), and AZ-PC (Fig. 1) were synthesized as described previ-
ously (16, 21, 22) and provided by Echelon Biosciences Inc.
SOV-PC (Fig. 1) was a gift from Dr. Judy Berliner (Uni-
versity of California, Los Angeles, Los Angeles, CA).
nLDL was purchased from Sigma-Aldrich, freed of
EDTA by desalting on PD10 columns (Amersham Bio-
sciences), and oxidized using Cu
 
2
 
 
 
 as a catalyst (14). Pro-
tein concentrations were determined using the BCA
protein assay kit (Pierce Chemical Co.). Final LDL con-
centrations were adjusted to 5 mg/ml before use. The
plasma LDL concentration is 1.6 mg/ml but in patients can
be as high as 8 
 
 
 
 6 mg/ml (23).
All procedures using animals have been reviewed and ap-
proved by the University of Tennessee Health Science Cen-
ter Memphis Institutional Animal Care and Use Committee.
Topical application of the test compounds was performed
using the model developed and characterized recently by
Yoshida et al. (17). Briefly, the right carotid artery of anes-
thetized adult male Sprague-Dawley rats (250–300 g) was
surgically exposed. The caudal origin of the common ca-
rotid artery (CCA) was ligated using a vessel clip, followed
by exposure and ligation of the internal carotid artery above
the bifurcation. The external carotid artery was exposed, and
a polyethylene catheter was inserted such that it never
reached the CCA, thereby avoiding mechanical injury to
the vessel. The clip occluding the CCA was temporarily re-
leased, and the vessel was rinsed with a retrograde injection
of 500 
 
 
 
l physiological saline to remove residual blood. The
vessel was again clipped, and 100 
 
 
 
l of treatment solution
was injected. After 60 min of incubation, the cannula was
withdrawn, the external carotid artery was ligated, and
blood flow was restored. Animals were allowed to recover
and were killed 7–56 d later by intracardiac perfusion of 10%
buffered formaldehyde (pH 7.4). The CCA from the jugular
arch to the bifurcation was dissected, embedded in paraffin,
and processed for histological analysis. 5-
 
 
 
m-thick sections
were cut and stained with hematoxylin and eosin or Mas-
son’s trichrome stain. Intima to media ratios were quantified
using an image analysis system (Scion Image CMS-800).
LPA and alkyl-GP species were extracted from nLDL
and moxLDL in acidic butanol followed by quantitative
analysis by stable isotope dilution electrospray ionization
mass spectrometry as described previously (24). CV-1 cells
were plated in 96-well plates (5 
 
 
 
 10
 
3
 
 cells per well) in
DME supplemented with 10% FBS. The next day, the cells
were transiently transfected with 125 ng of pGL3-PPRE–
acyl-CoA oxidase
 
 
 
(Acox)–renilla luciferase (Rluc), or 125
ng pGL3-CD36(-273), or pGL3-CD36(-261), 62.5 ng of
pcDNAI-PPAR
 
 
 
, and 12.5 ng of pSV–
 
 
 
-galactosidase
(Promega) using LipofectAMINE 2000 (Invitrogen). 24 h
after transfection, cells were treated with 1% FBS-supple-
mented OptiMEMI (Invitrogen) containing DMSO or test
compound (10 
 
 
 
M) in DMSO for 20 h. Luciferase and
 
 
 
-galactosidase activities were measured with the Steady-
Glo
 
®
 
 Luciferase Assay System (Promega) and the Galacto-
Light Plus™ System (Applied Biosystems), respectively.
Samples were run in quadruplicate, and the mean 
 
 
 
 SE
were calculated. Data are representative of at least three in-
dependent transfections. Student’s 
 
t
 
 test was used for null
hypothesis testing, and P
 
 
 
  
 
0.05 was considered significant.
Rat aortic VSMC cultures were established as described
by Hayashi et al. (18) in the presence of 2 ng/ml insulin-
like growth factor (IGF)-1. Sister cultures were established
in the presence of IGF-1 and treated with 1 
 
 
 
M of Rosi,
LPA 20:4, or LPA 20:0 on day 2 for an additional 3 d. Half
of the cultures received 200 nM GW9662 30 min prior ex-
posure to LPA and Rosi. Cell morphology was recorded
on day 5, and cells were harvested for mRNA extraction
and quantitative RT-PCR.
RT-PCR for LPA GPCR expression was done as de-
scribed earlier by Wang et al. (25). To quantify hCaD
mRNA, quantitative PCR was performed applying the real-
time SYBR Green PCR method using a Sequence Detec-
tion System Model 7700 (Applied Biosystems) instrument.
The rat hCaD and GAPDH (reference control mRNA)-
specific primers were designed with Primer Express Software
(Applied Biosystems), and forward and reverse primers were
as follows: 5
 
 
 
-GAACCAAAGCTGAGCAGGACA-3
 
 
 
 and
5
 
 
 
-TTCGTGCAGCCTCCATTCTT-3
 
 
 
 for hCaD; 5
 
 
 
-
AAGCTCACTGGCATGGCCTT-3
 
 
 
 and 5
 
 
 
-CGGCAT-
GTCAGATCCACAAC-3
 
 
 
 for GAPDH. The amplification
reaction was performed with SYBR Green PCR Master
Mix (Applied Biosystems) following the manufacturer’s pro-
tocol. mRNA abundance calculation was based on Ct values
as described previously (25). The expression level of hCAD
mRNA was normalized to GAPDH mRNA. Each PCR re- 
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action was performed at least three times, and the result was
expressed as mean 
 
 
 
 SEM. Statistical comparison of mRNA
expression was evaluated by ANOVA, and P 
 
  
 
0.05 was
considered statistically significant.
 
Results
 
To evaluate the effect of oxidatively modified LDL on
vascular remodeling, we treated the common carotid artery
of rats in situ for 1 h with nLDL and moxLDL using a pro-
cedure that avoided direct mechanical damage to the vessel.
This model was described recently and characterized by
Yoshida et al. (17). 2 wk after treatment, carotid arteries
were dissected en bloc and processed for histological evalua-
tion. moxLDL, but not nLDL, elicited pronounced and sig-
nificant neointima formation as illustrated in Fig. 2, A–C.
Minimal oxidization of LDL generates LPA-like biologi-
cal activity (8). LPA elicits numerous effects on cells of the
cardiovascular system including stimulation of platelet ag-
gregation, activation of macrophages and endothelial cells,
and the dedifferentiation and proliferation of VSMCs (8,
16, 18, 26–28). Many of these LPA-elicited cellular effects
are implicated in the development of neointima lesions.
Therefore, we hypothesized that oxidative modification of
LDL increases LPA levels in atherogenic moxLDL. The
concentrations of five acyl-LPA species were determined in
nLDL and moxLDL after copper-mediated minimal oxi-
dization (Fig. 3 A). Surprisingly, total acyl-LPA levels in
moxLDL were not significantly different (180 
 
 
 
 19 pmol/
mg LDL protein, 
 
n 
 
  
 
4) from the nLDL control (190 
 
 
 
 13
pmol/mg LDL protein, 
 
n 
 
  
 
4). However, there were sig-
nificant decreases in the concentration of polyunsaturated
acyl-LPA species in moxLDL, a finding consistent with ox-
idative degradation. Although the majority of LPA charac-
terized in biological fluids and tissues is the acyl form, the
alkyl ether glycerophosphate analogue, alkyl-GP, has also
been detected (29). Alkyl-GP has biological properties dis-
tinct from acyl-LPA. For example, alkyl-GP is 50 times
more potent than acyl-LPA in the activation of platelets
(12, 30, 31). We also quantified alkyl-GP levels in the LDL
preparations and found that alkyl-GP content was sixfold
higher in moxLDL, with the octadecenyl (18:1) species
showing a 10-fold increase over nLDL (Fig. 1 E and Fig. 3
B). Interestingly, the rank order of alkyl-GP species present
in moxLDL was the same as reported for the lipid core of
human atherosclerotic plaques (12).
Mild oxidation of LDL produces prothrombotic and
proatherogenic moxLDL (6, 8, 12). LPA GPCR antagonist
abolish platelet aggregation elicited by moxLDL, indicating
that LPA plays an essential role in the thrombogenic effects
of moxLDL (12). To define the contribution of LPA to the
neointima-inducing potential of moxLDL, we determined
the effect of various alkyl-GP and acyl-LPA species on
neointima formation in the rat carotid artery model (Fig. 3
C). 1-
 
O
 
-octadecenyl-glycerophosphate (1AGP; the natural
stereoisomer) was highly effective, whereas 3-
 
O
 
-octadece-
nyl-glycerophosphate (3AGP; the unnatural stereoisomer)
was modestly effective in eliciting neointima. The ether
bond in alkyl-GP is resistant to cleavage by phospholipases
A. Consequently, the metabolic conversion of alkyl-GP–
derived fatty alcohols can be ruled out, suggesting that in-
tracellular phospholipases of the A
 
1
 
 type are not involved in
generating a bioactive metabolite of alkyl-GP. 2,3-Cyclic
phosphatidic acid (cPA; 18:1), an endogenous, unsaturated
acyl-LPA analogue containing a cyclic phosphate, was in-
active. Unlike alkyl-GP, cPA18:1 is a substrate for phos-
pholipases A. Hence, the lack of its neointima-inducing ac-
tion indicates that oleic acid, a potential hydrolysis product
of cPA 18:1, is not sufficient to elicit this response. To-
gether, these results indicate a stereospecific requirement
for both an unsaturated fatty acid/fatty albyl group and a
free phosphate on the glycerol backbone in order to stimu-
late neointima formation.
Activation of platelets results in LPA production, which is
dominated by the polyunsaturated 20:4 (arachidonoyl) and
18:2 (linoleoyl) acyl species. Since LPA activates platelet ag-
gregation, LPA production from platelets sets up a feed for-
ward regulation mechanism that perpetuates platelet activa-
Figure 2. moxLDL treatment induces neointima formation in rat carotid arteries. Representative views of Masson’s trichrome-stained, paraffin-
embedded sections from animals treated with nLDL (A) or moxLDL (B) (5 mg LDL protein/ml) 2 wk after a 1-h treatment. Bar, 500  m. Intima to media
ratios were quantified (C, n   5). 
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tion and the production of LPA species enriched in
polyunsaturated fatty acids (24). Yoshida et al. (17) showed
in the rat that LPA species containing unsaturated fatty acyl
groups 16:1, 18:1, and 18:2 induced formation of neointi-
mal lesions, whereas the saturated acyl-LPA species were in-
active (Fig. 3 C). We exposed rat carotid arteries for 1 h to
LPA 20:4 or 20:0 and monitored vascular remodeling for up
to 8 wk posttreatment. LPA 20:4 was chosen because it is
the most abundant species in human serum (
 
 
 
40% of total
[24, 32]) with concentrations up to 2.5 
 
 
 
M. In contrast, the
total circulating concentration of acyl-LPA in plasma is
 
 
 
0.1 
 
 
 
M (24). This brief exposure to 2.5 
 
 
 
M LPA 20:4
elicited progressive neointimal growth, whereas 2.5 
 
 
 
M
LPA 20:0 was completely inactive (Fig. 4 A). The extent of
neointima development elicited by LPA 18:1 treatment was
concentration dependent up to 10 
 
 
 
M, the highest concen-
tration tested and reached statistical significance at 5 
 
 
 
M
(P
 
 
 
 
 
 0.01; Fig. 4 B). This concentration is equivalent to the
total LPA concentration found in human serum (24).
LPA is a growth factor-like phospholipid mediator that
activates specific G protein–coupled plasma membrane re-
ceptors LPA
 
1
 
, LPA
 
2
 
, and LPA
 
3 
 
encoded by the endothelial
differentiation gene family (33) and the distantly related
Figure 3. The five most abundant acyl-LPA (A) and alkyl-GP (B)
species were quantified in nLDL and moxLDL using stable isotope dilu-
tion electrospray ionization mass spectrometry. The lack of difference in
the total acyl-LPA content between nLDL and moxLDL is in sharp
contrast to the sixfold increase in alkyl-GP levels in moxLDL (n   4).
In the batch of nLDL used in the experiments shown in Figs. 2 and 3,
the alkyl-GP concentration was 0.1  M, and the total concentration of
unsaturated LPA plus alkyl-GP was 0.5  M, whereas in moxLDL these
concentrations were 0.7 and 0.9  M, respectively. (C) Structure-activity
relationship of neointimal lesion induction for various acyl-LPA (10
 M) and alkyl-GP (AGP) species (10  M). Only select LPA species
elicit neointima as the effect was stereoselective with a preference for
1AGP over 3AGP. LPA 18:0 and cPA 18:1 did not elicit detectable
neointima (for structural formulas see Fig. 1).
Figure 4. (A) Exposure of rat carotid arteries for 1 h to 2.5  M LPA
20:4, but not to LPA, 20:0 elicited progressive growth of neointima that
continued for up to 8 wk posttreatment. Quantitative morphometric
analysis for groups of 5 animals. (B) Dose–response curve for LPA 18:1-
elicited neointimal response. Mean (  SE) intima to media ratios were
determined for groups of five animals 2 wk after treatment.Select LPA Elicit Neointima Formation via PPAR  768
LPA4 (34). RT-PCR analysis using gene-specific primers
showed dominant expression of LPA1, low levels of LPA4,
and no transcripts for LPA2 or LPA3 in untreated rat carotid
arteries (Fig. 3 A and Fig. 5 A).
LPA GPCRs are activated by both saturated and unsat-
urated acyl-LPA species with a rank order of potency of
acyl-LPA alkyl-GP cPA (35). Moreover, LPA GPCRs
do not show stereoselectivity to alkyl-GP (21). The struc-
ture-activity relationship for LPA-induced neointima for-
mation was markedly different from that described for LPA
GPCR. First, neointima formation shows a rank order of
alkyl-GP acyl-LPA, with cPA being inactive. Second, un-
saturated but not saturated fatty acyl species stimulated le-
sion formation (Fig. 3 C). Third, formation of neointima
shows a stereoselective preference for 1-O-octadecenyl-GP
over 3-O-octadecenyl-GP. Fourth, in contrast to alkyl-GP
and unsaturated acyl-LPA, EGF (50 ng/ml), VEGF (10 ng/
ml), and PDGF (10 ng/ml) failed to induce detectable
neointima in this model after a 2-wk period (Fig. 5 B).
LPA GPCRs have been found to transactivate the EGF and
PDGF receptors (for review see reference 9); thus, the lack
of neointimal response to authentic ligands of these tyro-
sine kinase receptors discredits the involvement of such a
mechanism. Fifth, fluorinated LPA-like PPAR  agonists
that are four orders of magnitude less potent as LPA GPCR
agonists than LPA 18:1 (11) were nearly as potent at induc-
ing neointima formation in the rat model (Fig. 5 B). These
results lead to the conclusion that a receptor distinct from
known LPA GPCR mediates neointimal lesion formation.
LPA1-induced cell proliferation is fully blocked by per-
tussis toxin (PTX; 28). To examine the role of PTX-sensi-
tive G proteins in the neointimal response elicited by LPA,
vessels were treated with 100 ng/ml PTX for 30 min be-
fore and during LPA 20:4 exposure. PTX pretreatment at-
tenuated, but did not abolish, the response to LPA 20:4
(Fig. 6 A). Among LPA GPCRs, the LPA3 receptor is
unique with a preference for unsaturated LPA species (35).
However, RT-PCR analysis of normal carotid tissue
showed no detectable LPA3 transcript (Fig. 5 A). Likewise,
dioctylglycerol pyrophosphate (DGPP), a competitive an-
tagonist of the LPA3 and LPA1 receptors (36), produced a
modest inhibition (Fig. 6 A). These observations discount,
but do not completely exclude, a major role for LPA
GPCRs in neointima formation.
In addition to its plasma membrane receptors, LPA was
shown recently to be an agonist of the nuclear transcription
factor PPAR  (11). PPAR  has long been implicated in
atherogenesis (37, 38). PPARs are lipid-activated transcrip-
tion factors of the nuclear receptor superfamily that het-
erodimerize with the retinoic acid X receptor. PPAR/
retinoic acid X receptor heterodimers bind to specific per-
oxisome PPREs to regulate gene expression (39). Many
compounds activate PPAR, including the synthetic drug
Rosi of the thiazolidinedione (TZD) family, oxidized
phospholipids, fatty acids, eicosanoids, and oxidized LDL.
PPAR  is expressed in macrophages/monocytes, VSMCs,
endothelial cells, and is highly expressed in atherosclerotic le-
sions and hypertensive vascular wall (1, 37). PPAR  was de-
tected in normal rat carotid tissue by RT-PCR (Fig. 5 C).
For this reason, GW9662, a specific irreversible antagonist of
PPAR  (40), was applied at a concentration of 5  M 30 min
before and was coapplied with 2.5  M LPA 20:4. GW9662
completely abolished neointima formation elicited by LPA
20:4, indicating that PPAR  activation is required for the
development of LPA-induced lesion development (Fig. 6 B).
To further evaluate the hypothesis that PPAR  activation
leads to neointima formation, vessels were pretreated with
GW9662 or vehicle, with subsequent coapplication of the
PPAR  agonist Rosi. Rosi induced neointima formation
with a time course identical to that of LPA 20:4, indicating
that the activation of PPAR  is sufficient to elicit neointima
formation in this model (Fig. 6 B). Lesion formation by
Rosi was fully blocked by GW9662 treatment (Fig. 6 B).
The endogenous PPAR  agonist AZ-PC (16), an active
component of moxLDL, also caused neointima formation
that was inhibited by GW9662 (Fig. 6 B). Accordingly, the
neointima formed in response to moxLDL, LPA 20:4, and
LPA 18:1 was also inhibited by GW9662 pretreatment. In
contrast, treatment with the PPAR  agonist SOV-PC (41)
and saturated LPA species failed to stimulate neointima for-
mation, and GW9662 treatment had no effect on the vessels
from animals treated with these agents (Fig. 6 B). These re-
Figure 5. (A) RT-PCR of LPA GPCR in the rat carotid tissue. LPA1,
LPA4, and S1P1 were detected in RNA extracted from the whole carotid
tissue. (B) Effect of polypeptide growth factors and non-LPA GPCR
ligands fluorinated LPA analogs on neointima formation. Animals treated
with 10  M LPA 18:1, XY-4, and its regioisomer XY-8 but not those
treated with EGF (50 ng/ml), VEGF (10 ng/ml), PDGF-BB (10 ng/ml),
or LPA 18:0 (10  M) showed neointima formation. Groups of five animals
were treated with the compounds. (C) RT-PCR analysis detected
PPAR , PPAR , and PPAR  transcripts in the normal carotid tissue.Zhang et al. 769
sults together with those obtained with the PPAR  agonists
XY-4 and XY-8 (Fig. 5 B) support an essential role for
PPAR  activation in neointima formation in our model.
The structural requirements of LPA-elicited neointima
formation are distinct from those of any known LPA
GPCRs. Therefore, we compared the unique in vivo
neointima-eliciting LPA structure-activity relationship with
that of PPAR  using an in vitro assay that utilizes an acyl-
coenzyme A oxidase-luciferase (PPRE-Acox-Rluc) re-
porter gene construct containing PPRE (11). CV1 cells
were transiently transfected with PPAR  and PPRE-Acox-
Rluc and exposed to various LPA analogs for 20 h. Results
from this assay (Fig. 6 C) were identical to the structure-
activity relationship found in vivo (Fig. 3 C). Rosi, unsatur-
ated acyl-LPA species, and alkyl-GP all elicited significant
activation of the PPRE-Acox-Rluc reporter, whereas satu-
rated acyl LPA species, cPA, and the related lipid mediator
S1P were inactive. Interestingly, not only octadecenyl-GP
but also octadecyl-GP and hexadecyl-GP activated the re-
porter gene, indicating the unique properties of alkyl-GP
analogs in activating PPAR . Moreover, PTX and DGPP
treatment reduced but did not abolish activation of the
PPRE-Acox-Rluc reporter (Fig. 6 D), results that are con-
sistent with the in vivo experiments (Fig. 6 A). The dose–
response relationship of LPA- and Rosi-elicited activation
of the PPRE-Acox-Rluc reporter (Fig. 6, E and F) was
similar to that of the neointimal response (Fig. 4 B), al-
though with a lower threshold, as high nanomolar concen-
trations of the two PPAR  agonists were sufficient to cause
a significant activation of the receptor genes.
Expression of PPAR  protein in rat carotid arteries ex-
posed to LPA or moxLDL was examined. Immunohistologi-
Figure 6. (A) PTX and
DGPP, inhibitors of LPA GPCR
signaling, partially attenuated
neointima formation induced by
LPA 20:4, whereas the PPAR -
specific antagonist GW9662 com-
pletely  abolished this effect. (B)
Rosi, AZ-PC, moxLDL, and
unsaturated acyl forms of LPA all
induced neointima formation
that was completely abolished by
GW9662. In contrast, SOV-PC,
a PPAR -selective agonist, was
ineffective in stimulating the de-
velopment of neointima after 2
wk. (C) An in vitro assay using
CV1 cells transfected with
PPAR  and a PPRE-Acox-
Rluc reporter gene showed an
identical structure-activity rela-
tionship when exposed to different
LPA species as found for the
same set of ligands in the neoin-
tima assay in vivo (see Fig. 3 C).
(D) The PPAR  antagonist
GW9662  (10   M) abolished,
whereas PTX (100 ng/ml, 2 h)
and DGPP (10  M, 2 h) pre-
treatment and coapplication with
LPA partially inhibited LPA
20:4-induced PPRE-Acox-Rluc
reporter gene expression in vitro.
Vehicle contained 1% DMSO,
Rosi (10  M), LPA20:0 (10
 M), or LPA 20:0 (10  M)
were applied for 20 h. Luciferase
and   -galactosidase activities
(mean   SEM) were measured
in the cell lysate (n   4). (E and
F) Dose–response relationship of
LPA 20:4- and Rosi-induced
activation of PPRE-Acox-Rluc
reporter gene expression in
vitro. *P   0.05 and **P   0.01,
significant differences over vehicle
control.Select LPA Elicit Neointima Formation via PPAR  770
cal staining for the PPAR  antigen showed only a few
stained nuclei in arteries from animals treated with LPA 20:0
(Fig. 7 A) and nLDL (unpublished data). In contrast, intense
PPAR  immunoreactivity was observed in neointimal lesions
in carotid arteries from the LPA 20:4 (Fig. 7 B) and moxLDL
(unpublished data) treatment groups that strongly resembled
that reported previously in atherosclerotic lesions (1, 16, 37).
The scavenger receptor CD36, a PPAR -regulated
gene, contains a PPRE within its promoter between base
pairs –273 and –261 (11). CD36 plays a critical role in lipid
uptake by binding and transporting oxidized lipids, includ-
ing moxLDL (42). Thus, this pathway could provide a
source of ligands, such as LPA, alkyl-GP, and AZ-PC, to
sustain PPAR  activation. Acyl and alkyl forms of LPA
both accumulate in human atherosclerotic plaques (12).
LPA activates CD36-mediated lipid uptake into macro-
phages through a PPAR -PPRE–dependent mechanism
(11). Immunostaining for the CD36 antigen showed no in-
crease in immunoreactivity in vessels treated with LPA
20:0 (Fig. 3 F and Fig. 7 C) or nLDL (unpublished data).
However, neointimal tissue derived from treatment with
LPA 20:4 (Fig. 7 D) and moxLDL (unpublished data)
Figure 7. (A) Only a few nuclei
show PPAR  immunoreactivity
(in a carotid artery 4 wk after
treatment with 2.5  M LPA
20:0). In contrast, the multilay-
ered neointima elicited by LPA
20:4 (B) expresses high levels of
PPAR  immunoreactivity. Bars,
250  m. Activation of PPAR 
within neointima in LPA 20:4-
treated carotid arteries is indi-
cated by the strong expression of
CD36 in a distribution that over-
laps that of PPAR  (D). Little
immunoreactivity for CD36 was
noted in LPA 20:0-treated ani-
mals (C). Anti-PPAR  and anti-
CD36 were from Santa Cruz
Biotechnology, Inc. (E) Stimula-
tion of CD36( 271)-Rluc and
CD36( 261)-Rluc reporter
genes by Rosi, LPA, and AGP
in CV-1 cells. Rosi and LPA
20:4 but not LPA 20:0 (all 10
 M) elicited significant stimula-
tion of CD36( 273)-Rluc that
contains a PPRE between bp
 273 and  261. Neither com-
pound caused stimulation of the
CD36( 261)-Rluc. 1AGP showed
higher stimulation compared with
3AGP of the expression of the
Rluc reporter. (F) Plasma and
serum factors inhibit Rosi- and
LPA 20:4-induced neointimal
lesion formation in rat carotid ar-
teries. Rosi (10  M) and LPA
20:4 (2.5  M) elicited neointima
formation 2 wk after treatment
when delivered as BSA complexes.
In contrast, when the compounds
were delivered in rat plasma or
serum no neointima formation
was detected (n   5). Effect of BSA
(G) or serum (H) on PPAR  ac-
tivation by CPA and Rosi. Zhang et al. 771
showed intense CD36 immunoreactivity. The up-regu-
lated expression of CD36 suggests that PPAR  is activated
in LPA 20:4- and moxLDL-elicited neointimal lesions.
When tested in vitro using CV1 cells transfected with two
CD36-luc reporter constructs, one with and one without
the PPRE between –273 and –261, Rosi, LPA 20:4, and
alkyl-GP up-regulated the expression of a CD36-luc re-
porter gene, whereas LPA 20:0 was inactive (Fig. 7 E).
This activation was dependent on the presence of the
PPRE because neither Rosi nor LPA 20:4 activated the re-
porter gene with a deleted PPRE. Interestingly, whereas
activation by alkyl-GP was much reduced in the PPRE de-
letion mutant it was not completely abolished, suggesting
that in CV-1 cells other promoter elements might also be-
come activated by this ligand but not by LPA 20:4.
There is  0.1  M LPA in plasma and TZD drugs are
now being used for the treatment of diabetics, yet there are
no reports of increased vascular complications in these pa-
tients. To resolve this apparent controversy, we tested
whether plasma factors could attenuate the neointima-
inducing effects of Rosi and/or LPA. This hypothesis is
based on earlier reports showing that LPA diluted in plasma
and high concentrations of albumin shows diminished bio-
logical responses (32, 43). Heparinized, syngeneic plasma, or
serum was compared with serum albumin (2.5  M) as the
vehicle for Rosi and LPA 20:4 delivery. Only those animals
receiving Rosi or LPA 20:4 complexed with 2.5  M albu-
min developed neointimal lesions, whereas those that re-
ceived the compounds delivered in plasma or serum
showed no significant neointima formation (Fig. 7 F). Nei-
ther plasma nor serum alone had neointima-inducing ef-
fects (Fig. 7 F). This suggests that plasma and serum factors
attenuate formation of neointima and serve to mitigate
widespread effects of endogenous LPA and suppress the ef-
fect of Rosi. LPA present in serum readily activates LPA
GPCR-mediated biological responses (43–45); thus, the
lack of activity of serum and LPA delivered in serum points
to an important difference in the ligand recognition of LPA
GPCR versus PPAR . Moreover, Tokumura et al. (46)
reported that the transbilayer movement of alkyl-GP is
blocked by high concentrations (2%) of albumin, whereas it
remains substantial at low albumin concentrations (0.05%),
which is similar to what we used in our assays. To further
substantiate the notion that transbilayer movement of LPA
and Rosi could be affected by albumin and plasma/serum
factors in a concentration-dependent manner, we applied
the PPRE-Acox-Rluc reporter assay. Addition of albumin
(0.04–4% wt/vol; Fig. 7 G) or serum (1–20% vol/vol; Fig.
7 H) inhibited LPA- and Rosi-induced activation of the
PPRE-Acox-Rluc reporter gene in a concentration-
dependent manner, providing further support to the hy-
pothesis that carrier proteins could provide a physiological
barrier to the transbilayer movement of these ligands, thus
preventing/attenuating activation of PPAR .
Figure 8. PPAR  agonists elicit pheno-
typic modulation and dedifferentiation of
VSMCs in vitro. VSMC cultures established
in the presence of 2 ng/ml IGF-1 (A) were
treated with 1  M of each LPA 20:0 (C),
LPA 20:4 (E), and Rosi (G) for 3 d. LPA
20:4 and Rosi treatments lead to a pro-
nounced change in the morphology of
VSMCs. Pretreatment of the cultures with
200 nM GW9662 for 30 min did not affect
the spindle-like morphology of the IGF-1–
(B) and LPA 20:0-treated cultures (D). In
contrast, GW9662 reversed the flattened
morphology into a spindle-like shape in
cultures treated with LPA 20:4 (F) and Rosi
(H, calibration bar 100  m). Expression of
hCAD mRNA decreased significantly by
day 5 in VSMCs treated with Rosi and LPA
(I, white bars) compared with the IGF-treated
control cultures. This trend was reversed in
cultures pretreated with 200 nM GW9662
(I, black bars) as the PPAR  antagonist
caused a significant increase in the abundance
of hCAD mRNA measured by quantitative
RT-PCR (P   0.01, ANOVA).Select LPA Elicit Neointima Formation via PPAR  772
Hayashi et al. (18) reported that unsaturated LPA species
induced phenotypic modulation of cultured VSMCs. Be-
cause the neointimal response and PPAR  display a similar
selectivity for unsaturated LPA, we hypothesized that activa-
tion of PPAR  plays a role in the phenotypic dedifferentia-
tion. We tested this hypothesis in the same experimental
paradigm used by Hayashi et al. In this culture system, IGF-1
maintains the differentiated spindle shape of VSMCs, indi-
cated by high levels of hCAD mRNA expression (18).
VSMCs established in the presence of 2 ng/ml IGF-1 for 2 d
were exposed to 1  M of either Rosi, LPA 20:4, or LPA
20:0 for 3 d with or without 200 nM GW9662. Those
VSMCs exposed to Rosi and LPA 20:4 developed a fibro-
blast-like flattened morphology (Fig. 8, E and G), whereas
cultures exposed to LPA 20:0 (Fig. 8 C) maintained the
spindle-like differentiated morphology seen in the IGF-1–
treated controls (Fig. 8 A). GW9662 treatment reversed this
effect of LPA 20:4 and Rosi (Fig. 8, F and H). Using quanti-
tative RT-PCR, we found that hCAD mRNA expression
decreased by all treatments but was most pronounced in
VSMCs exposed to LPA 20:4 and Rosi (Fig. 8 I). GW treat-
ment caused a significant increase in hCAD mRNA expres-
sion. These results support the hypothesis that PPAR  plays
an essential role in the phenotypic modulation of VSMCs.
Discussion
Here we show that VSMCs and unsaturated acyl species
of the phospholipid mediator LPA elicit progressive and
long-lasting neointima formation in the rat carotid artery
that requires activation of PPAR . The structure-activity
relationship for lesion development is distinct from that of
known LPA GPCR. These data support the hypothesis
that the LPA-induced neointimal response is mediated by a
novel receptor. We propose that the relevant receptor is
PPAR . The synthetic PPAR  ligands Rosi, XY-4,
XY-8, and AZ-PC mimic the effect of LPA both in vivo
and in vitro. Accordingly, the PPAR -specific antagonist
GW9662 completely abolished the effect of Rosi, AZ-PC,
moxLDL, and LPA20:4. In contrast, the PPAR  receptor
ligand SOV-PC, as well as EGF, VEGF, and PDGF, and
saturated acyl LPA failed to stimulate neointima formation
in this model. Hayashi et al. (18) reported that only unsat-
urated LPA species were effective in eliciting VSMC dedif-
ferentiation in vitro. Using the same culture condition de-
scribed by these authors, we confirmed that the phenotypic
modulation of VSMCs was elicited by LPA 20:4 and estab-
lished that Rosi mimicked this effect. Phenotypic modula-
tion of VSMCs and the decrease in hCAD mRNA expres-
sion elicited by these PPAR  agonists was abolished by
GW9662. The structure-activity relationship of the pheno-
typic modulation of VSMCs agrees with that of the neoin-
timal lesions and activation of PPAR  in our experiments.
TZD drugs, including Rosi, are widely used in the treat-
ment of type 2 diabetes, yet patients taking these drugs do
not develop vascular complications above those associated
with their primary disease (47). It is tempting to propose
that neointima formation elicited by LPA could lead to
atherogenesis; however, these two phenomena, although
interrelated, depend on highly complex cellular and meta-
bolic events that occur over long periods of time. Conse-
quently, the present results pertain only to neointima for-
mation elicited by topical application of LPA and PPAR 
agonists in buffers that have low concentrations of carrier
proteins (0.05% BSA). TZD PPAR  agonists have been re-
ported to mitigate atherosclerosis in patients with type II
diabetes (48). In this context, we emphasize that TZD have
multiple effects on glucose and lipid metabolism and in-
flammatory cellular responses, some of which are not medi-
ated by PPAR  (49). Due to this complexity of TZD ef-
fects, we adapt the hypothesis put forward by Chawla et al.
(49) that the consequence of PPAR  activation may be
atherogenic in some contexts and protective in others as
determined by cellular context. The single and brief topical
application of LPA and Rosi in the present model, although
at physiologically and therapeutically relevant concentra-
tions, is not representative of systemic and chronic applica-
tion. However, one must take into consideration that the
manifestation of atherosclerotic disease spans decades.
A pressing question remains: how does extracellularly ap-
plied LPA find its way to the nuclear transcription factor
PPAR ? Transbilayer movement of phospholipids has been
thoroughly investigated and established for phosphatidic acid
(46, 50), platelet-activating factor (PAF) (46, 50), lyso-PAF
(51), LPA, S1P (52), 1-O-alkyl-2–acetyl-GP, and alkyl-GP
(46). Tokumura et al. (46) using alkyl-GP and its 2-acetyl
analogue showed that within 30 min of extracellular applica-
tion a steady-state condition develops with as much as 10–
14% of the intact lipid present in the intracellular membrane
compartment and the endoplasmic reticulum, contiguous
with the nuclear membrane. Thus, the micromolar extracel-
lular concentrations of lipid mediators required to elicit the
neointimal response could sustain intracellular LPA concen-
trations in the hundred nanomolar range, an intracellular
concentration well in excess of the nanomolar KD for LPA
binding to PPAR . Many of these studies used the albumin
extraction method (53), which utilizes the high-affinity
binding of these lipids to albumin for their quantitative ex-
traction from the outer leaflet of the plasma membrane. Al-
bumin concentrations  2% will quantitatively extract LPA
from the outer leaflet and prevent its transbilayer movement.
Based on this observation, and our results shown in Fig. 7,
F–H, the inhibitory effect of plasma and serum could be due
to its high albumin concentration ( 4%). Notwithstanding,
the impact of plasma albumin on LPA bioactivity might be
limited when LPA is either generated locally by platelets.
LPA bound to other carriers than albumin, for example,
LDL and moxLDL in particular, are taken up by receptor-
mediated mechanisms and lead to the activation of PPAR .
Activation of GPCR signaling has been reported to augment
the transbilayer movement of PAF and lyso-PAF (51) and
could also enhance LPA uptake. This raises the possibility
that LPA GPCR activation could facilitate the transbilayer
movement of LPA, providing an explanation for the attenu-Zhang et al. 773
ating but not abrogating effect of PTX and DGPP we ob-
served with respect to neointimal response and PPAR  re-
porter gene activation.
Generation of an LPA-like biological activity during ox-
idative modification of LDL has been documented previ-
ously, and here we provide evidence that alkyl ether ana-
logs of LPA increase in moxLDL. LPA generated in
moxLDL has the ability to activate platelet LPA GPCR (8,
12) and lead to production of unsaturated LPA species,
which are likely to contribute to its thrombogenic and
atherogenic effects. Thus, it appears that LPA, through the
activation of platelets and up-regulation of CD36-mediated
moxLDL uptake, could provide a link between two feed-
forward loops; one, which leads to LPA production, and
another that delivers ligands to PPAR . These two path-
ways potentially participate in a synergistic mechanism that
leads to neointima formation and vascular wall remodeling.
We suggest that alkyl-GP, along with unsaturated acyl-
LPA, in addition to oxidized phosphatidylcholines (AZ-
PC), represent a novel group of bona fide endogenous
PPAR  ligands that modulate vascular remodeling.
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